다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Gastroenterology clinics of North America, v.39 no.3, 2010년, pp.721 - 726
Shanahan, Fergus , Collins, Stephen M.
AI-Helper
The viewpoints of enthusiasts and skeptics in relation to the role of probiotics should not be allowed to distract clinicians from the bigger issue, which is the pivotal role of the microbiota in the protection against many disorders and in the pathogenesis of others. However, all probiotics, like a...
Nat Rev Immunol Round 9 313 2009 10.1038/nri2515 The gut microbiota shapes intestinal immune responses during health and disease
Nature Turnbaugh 449 804 2007 10.1038/nature06244 The human microbiome project
Cell Garrett 140 859 2010 10.1016/j.cell.2010.01.023 Homeostasis and inflammation in the intestine
Gut Bernstein 57 1185 2008 10.1136/gut.2007.122143 Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases
Nat Rev Microbiol Lebeer 8 171 2010 10.1038/nrmicro2297 Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens
Proc Natl Acad Sci U S A Corr 104 7617 2007 10.1073/pnas.0700440104 Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118
PLoS Pathogens O’Mahony 4 8 2008 Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-κB activation
PLoS Biol Sonnenburg 4 2213 2006 10.1371/journal.pbio.0040413 Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host
Mol Syst Biol Kitano 2 2006 2006 10.1038/msb4100039 Robustness trade-offs and host-microbial symbiosis in the immune system
Pediatrics Deshpande 125 921 2010 10.1542/peds.2009-1301 Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates
Pediatrics Tarnow-Mordi 125 1068 2010 10.1542/peds.2009-2151 Probiotics reduce all-cause mortality and necrotizing enterocolitis: it is time to change practice
Pediatrics Soll 125 1071 2010 10.1542/peds.2010-0643 Probiotics: are we ready for routine use?
Proc Nutr Soc Hedin 66 307 2007 10.1017/S0029665107005563 Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials
Gut Marteau 55 842 2006 10.1136/gut.2005.076604 Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double-blind, placebo-controlled GETAID trial
Inflamm Bowel Dis Van Gossum 13 135 2007 10.1002/ibd.20063 Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after lleo-caecal resection
Gut Kruis 53 1617 2004 10.1136/gut.2003.037747 Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine
Lancet Rembacken 354 635 1999 10.1016/S0140-6736(98)06343-0 Nonpathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial
Gastroenterology Gionchetti 119 305 2000 10.1053/gast.2000.9370 Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial
Gut Mimura 53 108 2004 10.1136/gut.53.1.108 Once-daily high-dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis
Am J Gastroenterol Brenner 104 1033 2009 10.1038/ajg.2009.25 The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review
J Nutr Haller 140 690S 2010 Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome
J Nutr Wolvers 140 698S 2010 Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics
Am J Clin Nutr Wall 89 1393 2009 10.3945/ajcn.2008.27023 The metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues
Front Biosci Van Huynegem 14 4825 2009 10.2741/3571 Immunomodulation by genetically engineered lactic acid bacteria
Clin Gastroenterol Hepatol Braat 4 754 2006 10.1016/j.cgh.2006.03.028 A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.